Free Trial
ASX:RGT

Argent BioPharma (RGT) Stock Price, News & Analysis

About Argent BioPharma Stock (ASX:RGT)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer. The company was formerly known as MGC Pharmaceuticals Limited and changed it name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.

Receive RGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter.

RGT Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-17,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.32 million
Book Value
A($0.11) per share

Miscellaneous

Free Float
N/A
Optionable
N/A
Beta
1.05
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (ASX:RGT) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners